: The global leader in animal health, currently ranked as an "undervalued" wide-moat stock by Morningstar.

: A staple for value investors, focusing on its next-generation immunology drugs to offset the patent loss of its blockbuster drug Humira.

: Recognized for its strong clinical momentum in oncology and its leading HIV franchise, with consistent revenue growth reported recently. Global & High-Growth Tickers

: Identified by Morningstar as one of the most undervalued wide-moat stocks, currently trading below its fair value.